Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of recombinant SARS-CoV-2 vaccine (CHO cells) in adults
ChiCTR2000040153Phase 3Not yet recruiting
- Sponsor
- Hunan Provincial Center for Disease Control and Prevention
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hunan Provincial Center for Disease Control and Prevention. Primary endpoints: SARS-CoV-2 neutralizing antibody, RBD protein binding antibody (IgG) and 1 more. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000040153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040153.